{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:30:59Z","timestamp":1789425059554,"version":"build-2803163510"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Cutaneous melanoma (CM) is an aggressive and highly metastatic solid tumor\nassociated with drug resistance. Before 2011, despite therapies based on cytokines or\nmolecules inhibiting DNA synthesis, metastatic melanoma led to patient death within 18\nmonths from diagnosis. However, recent studies on bidirectional interactions between melanoma\ncells and tumor microenvironment (TME) have had a significant impact on the\ndevelopment of new therapeutic strategies represented by targeted therapy and immunotherapy.\nIn particular, the heterogeneous stromal fibroblast populations, including fibroblasts,\nfibroblast aggregates, myofibroblasts, and melanoma associated fibroblasts\n(MAFs), represent the most abundant cell population of TME and regulate cancer growth\ndifferently. Therefore, in this perspective article, we have highlighted the different impacts\nof fibroblast populations on cancer development and growth. In particular, we focused\non the role of MAFs in sustaining melanoma cell survival, proliferation, migration\nand invasion, drug resistance, and immunoregulation. The important role of constitutively\nactivated MAFs in promoting CM growth and immunoediting makes this cell type a\npromising target for cancer therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220620124138","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T06:44:23Z","timestamp":1655793863000},"page":"6159-6168","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Insights into Melanoma Fibroblast Populations and Therapeutic Strategy\nPerspectives: Friends or Foes?"],"prefix":"10.2174","volume":"29","author":[{"given":"Angelica","family":"Avagliano","sequence":"first","affiliation":[{"name":"Department of Public Health, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Arcucci","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3390\/ijms22105283","volume":"22","author":"Romano V.","year":"2021","unstructured":"Romano V.; Belviso I.; Venuta A.; Ruocco M.R.; Masone S.; Aliotta F.; Fiume G.; Montagnani S.; Avagliano A.; Arcucci A.; Influence of tumor microenvironment and fibroblast population plasticity on melanoma growth, therapy resistance and immunoescape. Int J Mol Sci 2021,22(10),5283","journal-title":"Int J Mol Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3389\/fonc.2020.00722","volume":"10","author":"Avagliano A.","year":"2020","unstructured":"Avagliano A.; Fiume G.; Pelagalli A.; Sanit\u00e0 G.; Ruocco M.R.; Montagnani S.; Arcucci A.; Metabolic plasticity of melanoma cells and their crosstalk with tumor microenvironment. Front Oncol 2020,10,722","journal-title":"Front Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/cam4.707","volume":"5","author":"Zhou L.","year":"2016","unstructured":"Zhou L.; Yang K.; Randall Wickett R.; Zhang Y.; Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development. Cancer Med 2016,5(7),1566-1579","journal-title":"Cancer Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1073\/pnas.88.14.6028","volume":"88","author":"Cornil I.","year":"1991","unstructured":"Cornil I.; Theodorescu D.; Man S.; Herlyn M.; Jambrosic J.; Kerbel R.S.; Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 1991,88(14),6028-6032","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"E1435","DOI":"10.3390\/cells8111435","volume":"8","author":"Avagliano A.","year":"2019","unstructured":"Avagliano A.; Ruocco M.R.; Nasso R.; Aliotta F.; Sanit\u00e0 G.; Iaccarino A.; Bellevicine C.; Cal\u00ec G.; Fiume G.; Masone S.; Masullo M.; Montagnani S.; Arcucci A.; Development of a stromal microenvironment experimental model containing proto-myofibroblast like cells and analysis of its crosstalk with melanoma cells: A new tool to potentiate and stabilize tumor suppressor phenotype of dermal myofibroblasts. Cells 2019,8(11),E1435","journal-title":"Cells"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1038\/sj.onc.1208685","volume":"24","author":"Cheng N.","year":"2005","unstructured":"Cheng N.; Bhowmick N.A.; Chytil A.; Gorksa A.E.; Brown K.A.; Muraoka R.; Arteaga C.L.; Neilson E.G.; Hayward S.W.; Moses H.L.; Loss of TGF-\u03b2 type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-\u03b1-, MSP- and HGF-mediated signaling networks. Oncogene 2005,24(32),5053-5068","journal-title":"Oncogene"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1046\/j.1523-1747.2001.00239.x","volume":"116","author":"Rappl G.","year":"2001","unstructured":"Rappl G.; Kapsokefalou A.; Heuser C.; R\u00f6ssler M.; Ugurel S.; Tilgen W.; Reinhold U.; Abken H.; Dermal fibroblasts sustain proliferation of activated T cells via membrane-bound interleukin-15 upon long-term stimulation with tumor necrosis factor-\u03b1. J Invest Dermatol 2001,116(1),102-109","journal-title":"J Invest Dermatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.7150\/jca.10865","volume":"6","author":"Zhou L.","year":"2015","unstructured":"Zhou L.; Yang K.; Andl T.; Wickett R.R.; Zhang Y.; Perspective of targeting cancer-associated fibroblasts in melanoma. J Cancer 2015,6(8),717-726","journal-title":"J Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature17392","volume":"532","author":"Kaur A.","year":"2016","unstructured":"Kaur A.; Webster M.R.; Marchbank K.; Behera R.; Ndoye A.; Kugel C.H.; Dang V.M.; Appleton J.; O\u2019Connell M.P.; Cheng P.; Valiga A.A.; Morissette R.; McDonnell N.B.; Ferrucci L.; Kossenkov A.V.; Meeth K.; Tang H.Y.; Yin X.; Wood W.H.; Lehrmann E.; Becker K.G.; Flaherty K.T.; Frederick D.T.; Wargo J.A.; Cooper Z.A.; Tetzlaff M.T.; Hudgens C.; Aird K.M.; Zhang R.; Xu X.; Liu Q.; Bartlett E.; Karakousis G.; Eroglu Z.; Lo R.S.; Chan M.; Menzies A.M.; Long G.V.; Johnson D.B.; Sosman J.; Schilling B.; Schadendorf D.; Speicher D.W.; Bosenberg M.; Ribas A.; Weeraratna A.T.; sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016,532(7598),250-254","journal-title":"Nature"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1158\/1541-7786.MCR-16-0319","volume":"15","author":"Guan X.","year":"2017","unstructured":"Guan X.; LaPak K.M.; Hennessey R.C.; Yu C.Y.; Shakya R.; Zhang J.; Burd C.E.; Stromal senescence by prolonged CDK4\/6 inhibition potentiates tumor growth. Mol Cancer Res 2017,15(3),237-249","journal-title":"Mol Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-20-0329","volume":"10","author":"Alicea G.M.","year":"2020","unstructured":"Alicea G.M.; Rebecca V.W.; Goldman A.R.; Fane M.E.; Douglass S.M.; Behera R.; Webster M.R.; Kugel C.H.; Ecker B.L.; Caino M.C.; Kossenkov A.V.; Tang H.Y.; Frederick D.T.; Flaherty K.T.; Xu X.; Liu Q.; Gabrilovich D.I.; Herlyn M.; Blair I.A.; Schug Z.T.; Speicher D.W.; Weeraratna A.T.; Changes in aged fibroblast lipid metabolism induce age-dependent melanoma cell resistance to targeted therapy via the fatty acid transporter FATP2. Cancer Discov 2020,10(9),1282-1295","journal-title":"Cancer Discov"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ncb3399","volume":"18","author":"Dror S.","year":"2016","unstructured":"Dror S.; Sander L.; Schwartz H.; Sheinboim D.; Barzilai A.; Dishon Y.; Apcher S.; Golan T.; Greenberger S.; Barshack I.; Malcov H.; Zilberberg A.; Levin L.; Nessling M.; Friedmann Y.; Igras V.; Barzilay O.; Vaknine H.; Brenner R.; Zinger A.; Schroeder A.; Gonen P.; Khaled M.; Erez N.; Hoheisel J.D.; Levy C.; Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol 2016,18(9),1006-1017","journal-title":"Nat Cell Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"17038","DOI":"10.1038\/cddiscovery.2017.38","volume":"3","author":"Granato G.","year":"2017","unstructured":"Granato G.; Ruocco M.R.; Iaccarino A.; Masone S.; Cal\u00ec G.; Avagliano A.; Russo V.; Bellevicine C.; Di Spigna G.; Fiume G.; Montagnani S.; Arcucci A.; Generation and analysis of spheroids from human primary skin myofibroblasts: An experimental system to study myofibroblasts deactivation. Cell Death Discov 2017,3,17038","journal-title":"Cell Death Discov"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3851576","DOI":"10.1155\/2019\/3851576","volume":"2019","author":"Hodorogea A.","year":"2019","unstructured":"Hodorogea A.; Calinescu A.; Antohe M.; Balaban M.; Nedelcu R.I.; Turcu G.; Ion D.A.; Badarau I.A.; Popescu C.M.; Popescu R.; Popp C.; Cioplea M.; Nichita L.; Hulea I.; Brinzea A.; Epithelial-mesenchymal transition in skin cancers: A review. Anal Cell Pathol (Amst) 2019,2019,3851576","journal-title":"Anal Cell Pathol (Amst)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1755-148X.2010.00807.x","volume":"24","author":"Koefinger P.","year":"2011","unstructured":"Koefinger P.; Wels C.; Joshi S.; Damm S.; Steinbauer E.; Beham-Schmid C.; Frank S.; Bergler H.; Schaider H.; The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigment Cell Melanoma Res 2011,24(2),382-385","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","volume":"76","author":"Yang X.","year":"2016","unstructured":"Yang X.; Lin Y.; Shi Y.; Li B.; Liu W.; Yin W.; Dang Y.; Chu Y.; Fan J.; He R.; FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 2016,76(14),4124-4135","journal-title":"Cancer Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"Flavell R.A.","year":"2010","unstructured":"Flavell R.A.; Sanjabi S.; Wrzesinski S.H.; Licona-Lim\u00f3n P.; The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010,10(8),554-567","journal-title":"Nat Rev Immunol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1158\/1078-0432.CCR-18-0125","volume":"24","author":"Cho H.","year":"2018","unstructured":"Cho H.; Seo Y.; Loke K.M.; Kim S.W.; Oh S.M.; Kim J.H.; Soh J.; Kim H.S.; Lee H.; Kim J.; Min J.J.; Jung D.W.; Williams D.R.; Cancer-stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF Secretion. Clin Cancer Res 2018,24(21),5407-5421","journal-title":"Clin Cancer Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1158\/0008-5472.CAN-15-2468","volume":"76","author":"Nwani N.G.","year":"2016","unstructured":"Nwani N.G.; Deguiz M.L.; Jimenez B.; Vinokour E.; Dubrovskyi O.; Ugolkov A.; Mazar A.P.; Volpert O.V.; Melanoma cells block pedf production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts. Cancer Res 2016,76(8),2265-2276","journal-title":"Cancer Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ajpath.2012.08.027","volume":"181","author":"Yin M.","year":"2012","unstructured":"Yin M.; Soikkeli J.; Jahkola T.; Virolainen S.; Saksela O.; H\u00f6ltt\u00e4 E.; TGF-\u03b2 signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol 2012,181(6),2202-2216","journal-title":"Am J Pathol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/jid.2015.279","volume":"135","author":"Hutchenreuther J.","year":"2015","unstructured":"Hutchenreuther J.; Vincent K.M.; Carter D.E.; Postovit L.M.; Leask A.; CCN2 expression by tumor stroma is required for melanoma metastasis. J Invest Dermatol 2015,135(11),2805-2813","journal-title":"J Invest Dermatol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.284.5415.770","volume":"284","author":"Artavanis-Tsakonas S.","year":"1999","unstructured":"Artavanis-Tsakonas S.; Rand M.D.; Lake R.J.; Notch signaling: Cell fate control and signal integration in development. Science 1999,284(5415),770-776","journal-title":"Science"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-397927-8.00007-5","volume":"65","author":"Shao H.","year":"2012","unstructured":"Shao H.; Huang Q.; Liu Z.J.; Targeting notch signaling for cancer therapeutic intervention. Adv Pharmacol 2012,65,191-234","journal-title":"Adv Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e38811","DOI":"10.1371\/journal.pone.0038811","volume":"7","author":"Liu Z.J.","year":"2012","unstructured":"Liu Z.J.; Li Y.; Tan Y.; Xiao M.; Zhang J.; Radtke F.; Velazquez O.C.; Inhibition of fibroblast growth by Notch1 signaling is mediated by induction of Wnt11-dependent WISP-1. PLoS One 2012,7(6),e38811","journal-title":"PLoS One"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e0248260","DOI":"10.1371\/journal.pone.0248260","volume":"16","author":"Shao H.","year":"2021","unstructured":"Shao H.; Moller M.; Cai L.; Prokupets R.; Yang C.; Costa C.; Yu K.; Le N.; Liu Z.J.; Converting melanoma-associated fibroblasts into a tumor-suppressive phenotype by increasing intracellular Notch1 pathway activity. PLoS One 2021,16(3),e0248260","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"14235","DOI":"10.1007\/s13277-016-5293-6","volume":"37","author":"Zhou L.","year":"2016","unstructured":"Zhou L.; Yang K.; Wickett R.R.; Kadekaro A.L.; Zhang Y.; Targeted deactivation of cancer-associated fibroblasts by \u03b2-catenin ablation suppresses melanoma growth. Tumour Biol 2016,37(10),14235-14248","journal-title":"Tumour Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1158\/2326-6066.CIR-18-0086","volume":"6","author":"Zhao F.","year":"2018","unstructured":"Zhao F.; Evans K.; Xiao C.; DeVito N.; Theivanthiran B.; Holtzhausen A.; Siska P.J.; Blobe G.C.; Hanks B.A.; Stromal fibroblasts mediate anti-pd-1 resistance via mmp-9 and dictate tgf\u03b2 inhibitor sequencing in melanoma. Cancer Immunol Res 2018,6(12),1459-1471","journal-title":"Cancer Immunol Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cas.12584","volume":"106","author":"Ohshio Y.","year":"2015","unstructured":"Ohshio Y.; Teramoto K.; Hanaoka J.; Tezuka N.; Itoh Y.; Asai T.; Daigo Y.; Ogasawara K.; Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. Cancer Sci 2015,106(2),134-142","journal-title":"Cancer Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1900161","DOI":"10.1183\/13993003.00161-2019","volume":"54","author":"Wollin L.","year":"2019","unstructured":"Wollin L.; Distler J.H.W.; Redente E.F.; Riches D.W.H.; Stowasser S.; Schlenker-Herceg R.; Maher T.M.; Kolb M.; Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019,54(3),1900161","journal-title":"Eur Respir J"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41416-020-01201-z","volume":"124","author":"Kato R.","year":"2021","unstructured":"Kato R.; Haratani K.; Hayashi H.; Sakai K.; Sakai H.; Kawakami H.; Tanaka K.; Takeda M.; Yonesaka K.; Nishio K.; Nakagawa K.; Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: Potential role of cancer-associated fibroblasts. Br J Cancer 2021,124(5),914-924","journal-title":"Br J Cancer"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1913791","DOI":"10.1080\/19420862.2021.1913791","volume":"13","author":"Waldhauer I.","year":"2021","unstructured":"Waldhauer I.; Gonzalez-Nicolini V.; Freimoser-Grundschober A.; Nayak T.K.; Fahrni L.; Hosse R.J.; Gerrits D.; Geven E.J.W.; Sam J.; Lang S.; Bommer E.; Steinhart V.; Husar E.; Colombetti S.; Van Puijenbroek E.; Neubauer M.; Cline J.M.; Garg P.K.; Dugan G.; Cavallo F.; Acuna G.; Charo J.; Teichgr\u00e4ber V.; Evers S.; Boerman O.C.; Bacac M.; Moessner E.; Uma\u00f1a P.; Klein C.; Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs 2021,13(1),1913791","journal-title":"MAbs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00018-020-03517-8","volume":"78","author":"\u00c9rsek B.","year":"2021","unstructured":"\u00c9rsek B.; Sill\u00f3 P.; Cakir U.; Moln\u00e1r V.; Bencsik A.; Mayer B.; Mezey E.; K\u00e1rp\u00e1ti S.; P\u00f3s Z.; N\u00e9meth K.; Melanoma-associated fibroblasts impair CD8+\u2009T cell function and modify expression of immune checkpoint regulators via increased arginase activity. Cell Mol Life Sci 2021,78(2),661-673","journal-title":"Cell Mol Life Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"23282","DOI":"10.18632\/oncotarget.7818","volume":"7","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Ertl H.C.J.; Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors. Oncotarget 2016,7(17),23282-23299","journal-title":"Oncotarget"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"15155","DOI":"10.1200\/JCO.2018.36.15_suppl.e15155","volume":"36","author":"Soerensen M.M.","year":"2018","unstructured":"Soerensen M.M.; Ros W.; Rodriguez-Ruiz M.E.; Robbrecht D.; Rohrberg K.S.; Martin-Liberal J.; Lassen U.N.; Bermejo I.M.; Lolkema M.P.; Tabernero J.; Safety, PK\/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP) 2018,36,15155"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"E836","DOI":"10.3390\/v11090836","volume":"11","author":"Albano F.","year":"2019","unstructured":"Albano F.; Vecchio E.; Renna M.; Iaccino E.; Mimmi S.; Caiazza C.; Arcucci A.; Avagliano A.; Pagliara V.; Donato G.; Palmieri C.; Mallardo M.; Quinto I.; Fiume G.; Insights into thymus development and viral thymic infections. Viruses 2019,11(9),E836","journal-title":"Viruses"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13040697","volume":"13","author":"Sunami Y.","year":"2021","unstructured":"Sunami Y.; B\u00f6ker V.; Kleeff J.; Targeting and reprograming cancer-associated fibroblasts and the tumor microenvironment in pancreatic cancer. Cancers (Basel) 2021,13(4),1-14","journal-title":"Cancers (Basel)"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.actbio.2021.09.003","volume":"135","author":"Hu S.","year":"2021","unstructured":"Hu S.; Ma J.; Su C.; Chen Y.; Shu Y.; Qi Z.; Zhang B.; Shi G.; Zhang Y.; Zhang Y.; Huang A.; Kuang Y.; Cheng P.; Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis. Acta Biomater 2021,135,567-581","journal-title":"Acta Biomater"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1021\/acs.molpharmaceut.1c00455","volume":"18","author":"Li W.","year":"2021","unstructured":"Li W.; Little N.; Park J.; Foster C.A.; Chen J.; Lu J.; Tumor-associated fibroblast-targeting nanoparticles for enhancing solid tumor therapy: Progress and challenges. Mol Pharm 2021,18(8),2889-2905","journal-title":"Mol Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejpb.2021.05.007","volume":"165","author":"Yunna C.","year":"2021","unstructured":"Yunna C.; Mengru H.; Fengling W.; Lei W.; Weidong C.; Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor. Eur J Pharm Biopharm 2021,165,75-83","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.1213353109","volume":"109","author":"Stylianopoulos T.","year":"2012","unstructured":"Stylianopoulos T.; Martin J.D.; Chauhan V.P.; Jain S.R.; Diop-Frimpong B.; Bardeesy N.; Smith B.L.; Ferrone C.R.; Hornicek F.J.; Boucher Y.; Munn L.L.; Jain R.K.; Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 2012,109(38),15101-15108","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2014.01.005","volume":"74","author":"Nishihara H.","year":"2014","unstructured":"Nishihara H.; Human pathological basis of blood vessels and stromal tissue for nanotechnology. Adv Drug Deliv Rev 2014,74,19-27","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2019.01.032","volume":"448","author":"Liu M.","year":"2019","unstructured":"Liu M.; Song W.; Huang L.; Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. Cancer Lett 2019,448,31-39","journal-title":"Cancer Lett"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.1021\/acsnano.8b01890","volume":"12","author":"Liu Q.","year":"2018","unstructured":"Liu Q.; Chen F.; Hou L.; Shen L.; Zhang X.; Wang D.; Huang L.; Nanocarrier-mediated chemo-immunotherapy arrested cancer progression and induced tumor dormancy in desmoplastic melanoma. ACS Nano 2018,12(8),7812-7825","journal-title":"ACS Nano"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.7150\/thno.24821","volume":"8","author":"Hou L.","year":"2018","unstructured":"Hou L.; Liu Q.; Shen L.; Liu Y.; Zhang X.; Chen F.; Huang L.; Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics 2018,8(14),3781-3796","journal-title":"Theranostics"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jconrel.2016.11.013","volume":"245","author":"Huo M.","year":"2017","unstructured":"Huo M.; Zhao Y.; Satterlee A.B.; Wang Y.; Xu Y.; Huang L.; Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 2017,245,81-94","journal-title":"J Control Release"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.biomaterials.2015.07.053","volume":"68","author":"Zhao Y.","year":"2015","unstructured":"Zhao Y.; Huo M.; Xu Z.; Wang Y.; Huang L.; Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials 2015,68,54-66","journal-title":"Biomaterials"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220620124138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/206198\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220620124138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:02:20Z","timestamp":1691596940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/206198\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220620124138","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}